Dexin Kong1, Takao Yamori, Kanami Yamazaki, Shingo Dan. 1. Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmaceutical Sciences and Research Center of Basic Medical Sciences, Tianjin Medical University, 22 Qixiangtai RD, Heping, Tianjin, 300070, China, kongdexin@tijmu.edu.cn.
Abstract
BACKGROUND: As accumulating evidences suggest close involvement of phosphatidylinositol 3-kinase (PI3K) in cancer, novel PI3K inhibitors such as ZSTK474, GDC-0941, NVP-BEZ235 and BKM-120 have been developed for cancer therapy. A high frequency of hotspot mutations known as E542K, E545K and H1047R in the PIK3CA gene, which encodes the catalytic subunit of PI3Kα, has been found in various types of human cancers. The hotspot PIK3CA mutations also lead to resistance to therapeutics targeting epidermal growth factor receptor (EGFR), further suggesting that inhibition of hotspot mutant PIK3CA be required for a PI3K inhibitor as anticancer drug candidate. METHODS: To investigate the activity of the novel PI3K inhibitors on the hotspot mutant PIK3CA, we determined the inhibition against the respective recombinant mutant PI3Kαs by biochemical assay. We further examined the activity at cellular background by determining the effect on phosphorylation of Akt (Ser473), and that on the growth of cancer cells. In addition, apoptosis and autophagy in cells with or without hotspot PIK3CA mutation induced by the four inhibitors were investigated. RESULTS: Our results indicated that each inhibitor exhibit comparable activity on the hotspot mutant PI3Kα to that on the wild type, which was further demonstrated by the cell-based assays. No clear correlation was shown between the PIK3CA genetic status and the sensitivity for apoptosis or autophagy induction. Interestingly, among the 4 PI3K inhibitors, BKM-120 is the weakest in PI3K inhibitory potency, but induces most potent apoptosis, suggesting that BKM-120 might have a unique mode of action. CONCLUSIONS: Our result shows that the PI3K inhibitors exhibit potent activity on both hotspot mutant and wild type PI3Kα, suggesting they might be used to treat patients with or without PIK3CA mutation when approved.
BACKGROUND: As accumulating evidences suggest close involvement of phosphatidylinositol 3-kinase (PI3K) in cancer, novel PI3K inhibitors such as ZSTK474, GDC-0941, NVP-BEZ235 and BKM-120 have been developed for cancer therapy. A high frequency of hotspot mutations known as E542K, E545K and H1047R in the PIK3CA gene, which encodes the catalytic subunit of PI3Kα, has been found in various types of humancancers. The hotspot PIK3CA mutations also lead to resistance to therapeutics targeting epidermal growth factor receptor (EGFR), further suggesting that inhibition of hotspot mutant PIK3CA be required for a PI3K inhibitor as anticancer drug candidate. METHODS: To investigate the activity of the novel PI3K inhibitors on the hotspot mutant PIK3CA, we determined the inhibition against the respective recombinant mutant PI3Kαs by biochemical assay. We further examined the activity at cellular background by determining the effect on phosphorylation of Akt (Ser473), and that on the growth of cancer cells. In addition, apoptosis and autophagy in cells with or without hotspot PIK3CA mutation induced by the four inhibitors were investigated. RESULTS: Our results indicated that each inhibitor exhibit comparable activity on the hotspot mutant PI3Kα to that on the wild type, which was further demonstrated by the cell-based assays. No clear correlation was shown between the PIK3CA genetic status and the sensitivity for apoptosis or autophagy induction. Interestingly, among the 4 PI3K inhibitors, BKM-120 is the weakest in PI3K inhibitory potency, but induces most potent apoptosis, suggesting that BKM-120 might have a unique mode of action. CONCLUSIONS: Our result shows that the PI3K inhibitors exhibit potent activity on both hotspot mutant and wild type PI3Kα, suggesting they might be used to treat patients with or without PIK3CA mutation when approved.
Authors: T Yamori; A Matsunaga; S Sato; K Yamazaki; A Komi; K Ishizu; I Mita; H Edatsugi; Y Matsuba; K Takezawa; O Nakanishi; H Kohno; Y Nakajima; H Komatsu; T Andoh; T Tsuruo Journal: Cancer Res Date: 1999-08-15 Impact factor: 12.701
Authors: Douglas A Levine; Faina Bogomolniy; Cindy J Yee; Alex Lash; Richard R Barakat; Patrick I Borgen; Jeff Boyd Journal: Clin Cancer Res Date: 2005-04-15 Impact factor: 12.531
Authors: P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd Journal: J Natl Cancer Inst Date: 1990-07-04 Impact factor: 13.506
Authors: Ta-Jen Liu; Dimpy Koul; Tiffany LaFortune; Ningyi Tiao; Rui Jun Shen; Sauveur-Michel Maira; Carlos Garcia-Echevrria; W K Alfred Yung Journal: Mol Cancer Ther Date: 2009-08-11 Impact factor: 6.261
Authors: Douglas W McMillin; Melissa Ooi; Jake Delmore; Joseph Negri; Patrick Hayden; Nicolas Mitsiades; Jana Jakubikova; Sauveur-Michel Maira; Carlos Garcia-Echeverria; Robert Schlossman; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson; Constantine S Mitsiades Journal: Cancer Res Date: 2009-07-07 Impact factor: 12.701
Authors: Adrian J Folkes; Khatereh Ahmadi; Wendy K Alderton; Sonia Alix; Stewart J Baker; Gary Box; Irina S Chuckowree; Paul A Clarke; Paul Depledge; Suzanne A Eccles; Lori S Friedman; Angela Hayes; Timothy C Hancox; Arumugam Kugendradas; Letitia Lensun; Pauline Moore; Alan G Olivero; Jodie Pang; Sonal Patel; Giles H Pergl-Wilson; Florence I Raynaud; Anthony Robson; Nahid Saghir; Laurent Salphati; Sukhjit Sohal; Mark H Ultsch; Melanie Valenti; Heidi J A Wallweber; Nan Chi Wan; Christian Wiesmann; Paul Workman; Alexander Zhyvoloup; Marketa J Zvelebil; Stephen J Shuttleworth Journal: J Med Chem Date: 2008-09-25 Impact factor: 7.446
Authors: Wani Arjumand; Cole D Merry; Chen Wang; Elias Saba; John B McIntyre; Shujuan Fang; Elizabeth Kornaga; Prafull Ghatage; Corinne M Doll; Susan P Lees-Miller Journal: Oncotarget Date: 2016-12-13